SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around upcoming utilities like staking and a mobile app, alongside planned token burns upon reaching watcher milestones. Active community engagement, the consistent efforts of the development team, and the coin's listing on a centralized exchange are also key drivers. The community emphasizes long-term growth, shrugging off market dips, while focused on building value and reaching new milestones.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses its potential, citing Real World Asset (RWA) narratives and the possibility of a cup and handle forming. Some users are suggesting that Pyth is next to pump, while others are focusing on key resistance levels to break. The recent Innovative Finance Day announcement has also captured the attention of investors.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as a Bitcoin-native meme coin launched via the Runes protocol, sparking community excitement around its fair distribution and potential to outperform other meme coins. Many see it as a key player in the Bitcoin meme economy, emphasizing its security and direct contribution to Bitcoin mining. Discussions also highlight the growing #DOGArmy and speculation around potential tier-1 exchange listings.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending amid speculation around potential AI integration and renewed buyout rumors, fueled by chatter on WallStreetBets. Community members are actively discussing possible acquirers, the stock's high short interest, and potential catalysts for a price surge. Some traders are pointing to the stock revisiting key support levels as a possible indicator of upward momentum.

Wayfair, Inc. engages in an online home furnishing store. It operates through the U.S. and International segments. The U.S. segment consists of amounts earned through product sales through the company's five distinct sites in the U.S. and through websites operated by third parties in the U.S. The International segment is composed of earnings through product sales in international sites. The company was founded by Steven K. Conine and Niraj S. Shah in May 2002 and is headquartered in Boston, MA.

Wayfair Inc - Ordinary Shares - Class A

Wayfair Inc

Wayfair is trending due to a mix of factors, including tariff concerns and recent earnings. Community discussions revolve around the potential impact of tariffs on the company's international inventory, with some anticipating a significant drop, while others believe Wayfair is insulated. Bullish sentiment has grown recently with some traders pointing to the improved financials, technical indicators, and a possible short squeeze, while bearish traders cite a huge debt, an unsustainable valuation, and negative PE.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

DOG is trending as community members discuss its potential to outperform other meme coins like DOGE and SHIB, highlighting its fair launch on the Bitcoin network and strong community backing. Some believe DOG's unique position as the first fair-launched Bitcoin meme gives it an edge, with potential for tier-1 listings and widespread attention. Discussion also includes treasury stacking of DOG by CBLO as well as general sentiment around using DOG for downside protection.

WorldFinancial

WorldFinancial ($WLFI.X) is trending amidst discussions about its potential, real-world asset tokenization, and relationship with Justin Sun, with some investors believing it will reach the top 10 coins. The community is actively debating its association with the Trump family, the value of ALTS relative to WLFI, and whether it's a legitimate project or a scam. Overall, the conversation is focused on its future growth and potential as a stablecoin.

What is Tron? Tron's mission is to build a truly decentralized internet and aims to be the largest blockchain-based operating system in the world, known as the TRON protocol. The TRON protocol will offer high scalability, high availability, and high throughput computing to serve decentralized applications via smart contracts. Ethereum EVM-based smart contracts will be compatible and deployable on the TRON network as such Solidity developers do not have to rewrite their applications.  Why Tron? Since TRON protocol does not rely on proof of work or mining, instead governed by nodes located around the world, it is decentralized while providing high throughput for transactions on the blockchain. This is suitable for dapps that require high speed transactions especially games. There are a number of tokens already issued on the TRON network and the decentralized exchanges TRX.market has launched.  On July 24th 2018, TRON acquired BitTorrent, one of the largest P2P file sharing protocol. As a result of the acquisition, BitTorrent Token (BTT) was launched as the cryptocurrency to power the economics on the BitTorrent network. The Token will be used to inceltivize file sharing and storage within the network.

Tron

Tron is trending as discussions highlight its strong performance and stability compared to other cryptocurrencies, with some anticipating further gains and a potential move towards $1. Rumors of a connection to political figures and a reverse merger are circulating, while some community members express concern about potential scams and the project's leadership.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is trending as the community discusses its potential for real-world asset tokenization and recent developments, including a partnership facilitating compliant tokenized stocks. Community members are speculating on potential ETF filings and future price targets, remaining optimistic about HBAR's long-term utility and adoption in the financial sector. Discussions also involve meme coins built on the Hedera network.

Bonk is the first Solana dog coin for the people, by the people with 50% of the total supply airdropped to the Solana community. The Bonk contributors were tired of toxic “Alameda” tokenomics and wanted to make a fun memecoin where everyone gets a fair shot.

BONK

BONK.X is trending as the community discusses its potential, recent price movements, and future predictions, with some highlighting it as a symbol of the Solana community. There's debate around accumulation strategies and holding through dips, as well as comparisons to other meme coins. Some traders are also linking it to other Solana-based tokens and anticipating news.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax, Inc. (NVAX) announced on Thursday that its COVID-19 vaccine, Nuvaxovid, has been approved in Japan, triggering a milestone payment from Japanese pharmaceutical company Takeda.The vaccine was approved for initial immunization (first and second vaccinations) in individuals aged six years or older, and as a booster immunization (following the third vaccination) in individuals aged 12 years or older in the country.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVAX">NVAX stock</a> stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.Under Novavax’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.novavax.com/press-releases/2025-09-04-Nuvaxovid-R-Now-Approved-in-Japan-Triggering-Takeda-Milestone-Payment">deal</a> with Takeda, the company is also eligible to receive royalties on net sales of Nuvaxovid from Takeda in this vaccination season. The company did not disclose specific payment amounts, saying that it is bound by contractual confidentiality agreements.Novavax and Takeda updated the terms of their 2020 collaboration and licensing agreement for Nuvaxovid in May. The amended deal includes an upfront payment, a payment related to the 2024-2025 season, annual milestones associated with regulatory approvals, and royalties on net sales earned every season moving forward, the company stated. In the second quarter, the company reported $27 in licensing, royalties, and other revenue from Takeda.Novavax got the U.S. Food and Drug Administration’s approval for Nuvaxovid in May for the prevention of COVID-19 in adults 65 years and older and individuals aged 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from the disease. The FDA then requested the company to conduct a postmarketing commitment (PMC) study.However, Novavax <a href="https://stocktwits.com/news-articles/markets/equity/novavax-cfo-says-sanofi-to-cover-majority-of-future-nuvaxovid-study-costs/chrScEpRd50">stated</a> last month that the study will not impact its operating profit for 2025, as its partner, Sanofi, will cover the majority of the expenses.NVAX stock is down 9% this year and approximately 38% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/this-burger-chain-stock-has-gained-9-this-year-bmo-capital-sees-another-14-upside/chwdEPGRdYl">This Burger Chain Stock Has Gained 9% This Year And BMO Capital Sees Another 14% Upside – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a medical syringe is displayed on a screen, and the logo of Novavax in the background. (Photo Illustration by Nikos Pekiaridis/SOPA Images/LightRocket via Getty Images)

Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda

The vaccine was approved for initial immunization in individuals aged six years or older and as a booster immunization in those aged 12 years or older in the country. 

Equity

The vaccine was approved for initial immunization in individuals aged six years or older and as a booster immunization in those aged 12 years or older in the country. 


Boyd Gaming and Shoe Carnival have been highlighted as Zacks Bull and Bear of the Day

Boyd Gaming surges on strong earnings and growth plans, while Shoe Carnival struggles with sliding sales and weaker momentum.

FDA Approves Updated COVID-19 Vaccines but With Restrictions

FDA clears updated COVID-19 vaccines from Pfizer, Moderna and Novavax but limits access to older adults and high-risk groups.

Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

U.S. Health Secretary Robert F. Kennedy Jr. stated on Wednesday that the Food and Drug Administration (FDA) has now granted full marketing authorization for certain&nbsp;Covid&nbsp;vaccines targeting higher-risk groups.&nbsp;The health secretary said that the decision marks a transition away from pandemic-era emergency powers. “The American people demanded science, safety, and common sense. This framework delivers all three,” the secretary said, adding thanks to FDA official Dr. Marty Makary for his role in the process.Moderna’s (MRNA) shot has been authorized for individuals six months and older, Pfizer's (PFE) for ages five and up, and Novavax's (NVAX) for ages 12 and above. In a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/SecKennedy/status/1960742897201872969">post</a> on X, Kennedy stated that these will be available to patients who choose vaccination, in consultation with their doctors.&nbsp;<figure class="image"><img style="aspect-ratio:1080/1907;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_27_22_13_10_04_0b2fce7a16bf2b728d6ffa28c8d60efb_1_jpg_d5715c25ca.webp" alt="Screenshot_2025-08-27-22-13-10-04_0b2fce7a16bf2b728d6ffa28c8d60efb (1).jpg" width="1080" height="1907"><figcaption>Source: @SecKennedy/X</figcaption></figure>The news comes on the heels of a Daily Beast&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thedailybeast.com/donald-trump-and-robert-f-kennedy-junior-to-ban-covid-19-vaccine-within-months/">report</a> which stated that "a decision to remove the (COVID-19) vaccine from the U.S. market pending further research will come ‘within months,’" citing British cardiologist Dr. Aseem Malhotra.&nbsp;<a href="http://stocktwits.com/symbol/MRNA">Modern’s stock</a> edged 0.5% higher in afternoon trade with retail sentiment around the company moving higher within ‘extremely bullish’ territory over the past day.&nbsp;<a href="http://stocktwits.com/symbol/PFE">Pfizer’s stock</a> moved 0.4% higher, but retail sentiment continued to trend in the ‘neutral’ zone.&nbsp;<a href="http://stocktwits.com/symbol/NVAX">Novavax’s stock</a> was among the top trending stocks on the platform, but its price fell 0.5% and retail sentiment dipped to ‘neutral’ from the ‘bullish’ zone. The stock has fallen by more than 8% over the past week following the company's&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-suffers-sharpest-drop-in-months-after-225-m-debt-deal-retail-still-leans-bullish/chsmrNiRd0d">announcement</a> of its new debt refinancing plan.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/warner-bros-names-brad-singer-cfo-ahead-of-planned-spinoff/chsUE1pRdlI">Warner Bros. Names Brad Singer CFO Ahead Of Planned Spinoff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during a cabinet meeting with U.S. President Donald Trump on August 26, 2025 in Washington, DC. (Photo by Chip Somodevilla/Getty Images)

Robert Kennedy Jr. Announces End Of FDA Covid Mandates – Clears Moderna, Pfizer, Novavax For High-Risk Groups

Moderna’s Covid vaccine has been authorized for individuals six months and older, Pfizer's for ages five and up, and Novavax's for ages 12 and above. 

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Novavax slid Thursday in its worst session in more than four months after laying out plans to refinance $225 million of debt, a move that piled onto fresh concerns from a Bank of America downgrade and ongoing uncertainty around its COVID-19 vaccine business.The company said it worked out agreements with some of the holders of its 2027 convertible notes and new investors to replace them with new notes maturing in 2031.&nbsp;The deal covers about $175 million of new 2031 notes swapped for $148.7 million of existing 2027 notes, along with $50 million in fresh cash.&nbsp;The new notes can be converted at $11.14 a share, marking a 27.5% premium to Wednesday’s close, and are expected to be completed by Aug. 27, leaving just $26.5 million of the 2027 notes still outstanding.Novavax said the refinancing strengthens its balance sheet by pushing most debt out to 2031, but investors worried about fresh funding needs and share dilution, fueling the selloff.&nbsp;The drop came a day after Bank of America cut its rating to ‘Underperform’ from ‘Neutral’ and lowered its price target to $7 from $9, warning of an “increasingly murky outlook” for growth.The bank argued that Sanofi’s commercialization of the Nuvaxovid vaccine in the U.S. may face limits with a restricted label and fading demand for COVID shots even as new FDA rules could make future partnerships more expensive and harder to secure.Novavax reassured investors earlier this month, saying a postmarketing study requested by the FDA for&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-cfo-says-sanofi-to-cover-majority-of-future-nuvaxovid-study-costs/chrScEpRd50">Nuvaxovid won’t affect its 2025 operating profit</a> because Sanofi is covering most of the cost.&nbsp;CFO Jim Kelly said Sanofi is “picking up the vast majority of expenses.” The study, expected to run through 2025 and 2026, will cost an estimated $70 million to $90 million, with Sanofi reimbursing about 70%.On Stocktwits, retail sentiment toward Novavax was bullish with high message volume, placing it among the platform’s top-trending stocks.One retail trader on Stocktwits argued there was nothing fundamentally wrong with Novavax securing $50 million in fresh funding and refinancing its debt at a lower rate.&nbsp;The user added that partnership news was always the real potential catalyst and said the pullback into the $7 range should not have come as a surprise,&nbsp;given the spike seen earlier this week.<stembedurl>https://stocktwits.com/Imposter333/message/626160936</stembedurl>Another user said they were holding firm, noting they had not sold a single share of Novavax and continue to own 35,000 shares.<stembedurl>https://stocktwits.com/MM316/message/626159949</stembedurl><a href="https://stocktwits.com/symbol/NVAX">Novavax’s stock</a> has declined 5.1% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 Ampoules containing the new Corona vaccine Nuvaxovid from the manufacturer Novavax sit on a table at a vaccination center. Photo: Matthias Bein/dpa (Photo by Matthias Bein/picture alliance via Getty Images)

Novavax Stock Suffers Sharpest Drop In Months After $225M Debt Deal; Retail Still Leans Bullish

Bank of America’s downgrade to ‘Underperform’ with a $7 target deepened concerns over Sanofi’s limited commercialization of Nuvaxovid and higher hurdles for future partnerships. 

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View

Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.

Novavax Inc. (NVAX) on Wednesday said that the postmarketing commitment study for its COVID-19 vaccine Nuvaxovid will not have an impact on its operating profit for 2025.“Sanofi is picking up the vast majority of expenses as we keep the momentum, right, in the vaccine advancing in the marketplace,” Novavax CFO Jim Kelly said.Novavax got the U.S. Food and Drug Administration’s approval for Nuvaxovid in May for the prevention of COVID-19 in adults 65 years and older and individuals aged 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from the disease.The FDA then requested the company to conduct a postmarketing commitment (PMC) study.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVAX">NVAX</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_06_at_11_17_13_AM_png_79b8a2fc97.webp" alt="NVAX's Sentiment Meter and Message Volume as of 11:17 a.m. ET on Aug. 6, 2025 | Source: Stocktwits" width="627" height="62"><figcaption>NVAX's Sentiment Meter and Message Volume as of 11:17 a.m. ET on Aug. 6, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the company needs to diversify its partnership portfolio to prevent limiting its upside.<stembedurl>https://stocktwits.com/ReturnOfEsquire/message/623952283</stembedurl> Novavax on Wednesday <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.novavax.com/press-releases/2025-08-06-Novavax-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights">said</a> that the Nuvaxovid study is anticipated to occur during 2025 and 2026 and cost between $70 million and $90 million to complete. The company will conduct the study on behalf of its partner Sanofi, which will reimburse 70% of the total costs, or about $55 million.While Novavax is also expected to incur some costs, they are included within the company’s research and development expense targets and capped under the agreement with Sanofi, the company said.Novavax on Wednesday raised its annual adjusted revenue forecast to between $1 billion and $1.05 billion, from $975 million to $1.03 billion earlier.The company reported total revenue of $239 million, above an analyst estimate of $147.55 million, thanks to a $175 million milestone payment from Sanofi over the approval of Nuvaxovid.Transfer of marketing authorization of the vaccine to Sanofi for the U.S. and European Union markets is expected in Q4, which will trigger an additional $50 million in combined milestones from Sanofi, Novavax said.Novavax’s diluted net income per share came in at $0.62, above consensus estimates.NVAX stock is down by 6% this year and by about 35% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gm-secures-rare-earth-magnet-supply-from-texas-partner-amid-push-to-mitigate-tariffs/chrSGvqRd5B">GM Secures Rare Earth Magnet Supply From Texas Partner Amid Push to Mitigate Tariffs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Novavax CFO Says Sanofi To Cover Majority Of Future Nuvaxovid Study Costs, Retail Urges Partnership Diversification

Novavax on Wednesday said that the postmarketing commitment study is anticipated to occur during 2025 and 2026 and cost between $70 million and $90 million to complete.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVAX News

NVAX Novavax Inc